Supplemental material
Expert Opinion on Drug Safety
Volume 20, 2021 - Issue 3
Open access
3,748
Views
5
CrossRef citations to date
0
Altmetric
Original Research
Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance
Tomohiro Itoa Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanCorrespondence[email protected]
https://orcid.org/0000-0002-6456-2825View further author information
Yusuke Naitoa Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan
https://orcid.org/0000-0001-8033-6708View further author information
Naoki Shimmotoa Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanView further author information
, Kaori Ochiaib PMS Center, Real World Evidence Business Headquarters, EPS Corporation, Tokyo, JapanView further author information
, Naoyuki Hayashia Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanView further author information
& Tomoo Okamuraa Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanView further author information
Pages 363-372
|
Received 13 Nov 2020, Accepted 01 Dec 2020, Published online: 27 Dec 2020
Related Research Data
Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance
Source:
Taylor & Francis
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.